2nd progressive vision loss drug by Biogen fails in late-stage trial
June 14, 2021 at 16:49 PM EDT
Another gene therapy for progressive vision loss developed by Biogen Inc. (Nasdaq: BIIB) has failed in a late-stage clinical trial, the company announced Monday.
